Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies

In this interactive on-demand Webcast, expert faculty members discuss how they currently use CAR T-cells to treat hematologic malignancies and provide a look ahead at new data and promising agents that may soon change practice.
Renier J. Brentjens, MD, PhD
Program Director
Frederick L. Locke, MD
Noopur Raje, MD
Released: March 29, 2021 Expiration: No longer available for credit

Related Content

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Download these expert-selected slides on anti-BCMA CAR T-cell and bispecific agents for relapsed/refractory myeloma, from Clinical Care Options (CCO).

Noopur Raje, MD Released: September 22, 2022

Download these expert-selected slides on later-stage relapsed/refractory myeloma to help manage your patients, from Clinical Care Options (CCO).

Paul G. Richardson, MD Released: September 22, 2022

See key clinical insights fast, with this short slideset from CCO on relapsed/refractory myeloma, from Clinical Care Options (CCO).

Natalie S. Callander, MD Noopur Raje, MD Paul G. Richardson, MD Released: September 22, 2022
Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Kite Pharma

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings